Resistance Pattern in Mostly Gram-negative Bacteria Causing Urinary Tract Infections.

Q3 Pharmacology, Toxicology and Pharmaceutics
Bader S Alotaibi, Bilal Ahmad Tantry, Anjum Farhana, Muath A Alammar, Naveed Nazir Shah, Abdul Hafeez Mohammed, Farooq Wani, Altaf Bandy
{"title":"Resistance Pattern in Mostly Gram-negative Bacteria Causing Urinary Tract Infections.","authors":"Bader S Alotaibi,&nbsp;Bilal Ahmad Tantry,&nbsp;Anjum Farhana,&nbsp;Muath A Alammar,&nbsp;Naveed Nazir Shah,&nbsp;Abdul Hafeez Mohammed,&nbsp;Farooq Wani,&nbsp;Altaf Bandy","doi":"10.2174/1871526522666220928115043","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The antimicrobial prescription in urinary tract infections (UTI) is driven by local data on its pathogenic spectrum and the resistance pattern exhibited by the disease-causing pathogens. We aimed to determine the bacteriological diversity of UTI causing pathogens and antimicrobial resistance in mostly gram-negative bacteria.</p><p><strong>Methods: </strong>This retrospective hospital-based cross-sectional study analyzed the culture and sensitivity reports of urine samples from a referral centre in the Aljouf region of Saudi Arabia. All the antibiograms from January 1, 2020, to December 31st 2020, were included. The bacterial identification and antimicrobial testing were carried out by the BD Phoenix system (BD Diagnostics, Sparks, MD, USA). Antimicrobial testing was performed as per the Clinical and Laboratory Standard Institute recommendations. Frequencies of multidrug- and extensive drug resistance were calculated.</p><p><strong>Results: </strong>Of the 1334 non-duplicate urine samples received, 422 (31.6%) bacterial growths were observed. Of these, 383 (90.8%) and 39 (9.2%) were gram-negative and gram-positive bacterial isolations, respectively. E. coli 161 (38.1%), K. pneumoniae 97 (23.0%), and E. faecalis 18 (4.3%) were frequent aetiologies of UTI. 309 (80.7%) of gram-negative bacteria were multidrug-resistant including 88 (23.0%) extensively drug-resistant. Overall, a resistance rate of > 55 % to 1st through 4th generation cephalosporins was observed except for cefoxitin (43.7%). A resistance rate of 37.6% was observed towards carbapenems, with the lowest rate (34.0%) to meropenem.</p><p><strong>Conclusion: </strong>Multi-drug resistant gram-negative bacteria dominate the pathogenic spectrum of UTI in the region. A high resistance rate to cephalosporins and carbapenems exists in gram-negative organisms, causing UTI.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526522666220928115043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3

Abstract

Purpose: The antimicrobial prescription in urinary tract infections (UTI) is driven by local data on its pathogenic spectrum and the resistance pattern exhibited by the disease-causing pathogens. We aimed to determine the bacteriological diversity of UTI causing pathogens and antimicrobial resistance in mostly gram-negative bacteria.

Methods: This retrospective hospital-based cross-sectional study analyzed the culture and sensitivity reports of urine samples from a referral centre in the Aljouf region of Saudi Arabia. All the antibiograms from January 1, 2020, to December 31st 2020, were included. The bacterial identification and antimicrobial testing were carried out by the BD Phoenix system (BD Diagnostics, Sparks, MD, USA). Antimicrobial testing was performed as per the Clinical and Laboratory Standard Institute recommendations. Frequencies of multidrug- and extensive drug resistance were calculated.

Results: Of the 1334 non-duplicate urine samples received, 422 (31.6%) bacterial growths were observed. Of these, 383 (90.8%) and 39 (9.2%) were gram-negative and gram-positive bacterial isolations, respectively. E. coli 161 (38.1%), K. pneumoniae 97 (23.0%), and E. faecalis 18 (4.3%) were frequent aetiologies of UTI. 309 (80.7%) of gram-negative bacteria were multidrug-resistant including 88 (23.0%) extensively drug-resistant. Overall, a resistance rate of > 55 % to 1st through 4th generation cephalosporins was observed except for cefoxitin (43.7%). A resistance rate of 37.6% was observed towards carbapenems, with the lowest rate (34.0%) to meropenem.

Conclusion: Multi-drug resistant gram-negative bacteria dominate the pathogenic spectrum of UTI in the region. A high resistance rate to cephalosporins and carbapenems exists in gram-negative organisms, causing UTI.

大多数革兰氏阴性菌引起尿路感染的耐药模式。
目的:尿路感染(UTI)的抗菌药物处方是由当地的致病谱数据和致病病原体所表现出的耐药模式驱动的。我们的目的是确定尿路感染引起的病原体的细菌多样性和大多数革兰氏阴性菌的抗菌素耐药性。方法:这项以医院为基础的回顾性横断面研究分析了沙特阿拉伯Aljouf地区转诊中心尿液样本的培养和敏感性报告。纳入2020年1月1日至2020年12月31日的所有抗生素图。细菌鉴定和抗菌试验由BD Phoenix系统(BD Diagnostics, Sparks, MD, USA)进行。抗菌测试是按照临床和实验室标准研究所的建议进行的。计算了多药耐药和广泛耐药的频率。结果:收到的1334份非重复尿样中,有422份(31.6%)细菌生长。其中革兰氏阴性菌383株(90.8%),革兰氏阳性菌39株(9.2%)。大肠杆菌161(38.1%)、肺炎克雷伯菌97(23.0%)和粪肠杆菌18(4.3%)是尿路感染的常见病因。革兰氏阴性菌多重耐药309株(80.7%),广泛耐药88株(23.0%)。总体而言,除头孢西丁(43.7%)外,对第1 ~第4代头孢菌素的耐药率> 55%。对碳青霉烯类的耐药率为37.6%,对美罗培南的耐药率最低(34.0%)。结论:该地区尿路感染病原菌以多重耐药革兰氏阴性菌为主。革兰氏阴性菌对头孢菌素和碳青霉烯类具有较高的耐药率,可引起尿路感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infectious disorders drug targets
Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.10
自引率
0.00%
发文量
123
期刊介绍: Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信